A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT03328273 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: Ceralasertib
DRUG: Acalabrutinib

Sponsor

Acerta Pharma BV